Autobytel Boosts Guidance Significantly; Pershing Square Capital Sees Potential In Actavis

Author's Avatar
May 22, 2015

03May20171111321493827892.jpgAutobytel Inc. (ABTL, Financial)

Shares of ABTL soared to near 52-week high in extended-hours trading Thursday as the company said that it has acquired Dealix Corporation and Autotegrity, Inc. for $25 million in an all-cash transaction and raised its business outlook for 2015.

According to ABTL, the acquisition is expected to be accretive to net income in 2015 and adds approximately 600 retail new dealers and 300 retail used dealers to the company's network, for a combined total of approximately 4,954 automotive dealers.

Following the transaction, ABTL has revised its guidance for fiscal 2015 and now expects revenues to range between $128.0 million and $132.0 million, up from the previously issued revenue guidance range of $114.0 million to $120.0 million, and non-GAAP diluted earnings per share to range between $1.21 and $1.27, up from the previously reported non-GAAP diluted EPS range of $0.97 to $1.16.

03May20171111321493827892.png

ABTL provides high quality consumer leads and associated marketing services to automotive dealers and manufacturers throughout the United States.

More about Autobytel Inc. at www.autobytel.com

**

03May20171111331493827893.jpgActavis plc (ACT, Financial)

Billionaire William Ackman's Pershing Square Capital Management LP disclosed in a regulatory filing ( Form 13F-HR ) with the Securities and Exchange Commission (SEC) that it added 1,348,358 shares of ACT to its investment portfolio during the first quarter 2015.

ACT recently reported strong performance in its first quarter 2015 financial results, with net revenue increasing by 59% to $4.23 billion and non-GAAP diluted earnings per share increasing by 23% to $4.30 (versus the same period the prior year).

Including the Allergan business, which acquisition was completed in March this year, ACT expects for the full year 2015 pro forma net revenues in the range of $20.5 billion to $21.0 billion.

03May20171111331493827893.png

ACT is a global integrated specialty pharmaceutical company. It is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high quality generic and over-the-counter medicines and biologic products for patients around the world.

More about Actavis plc at www.actavis.com

**

03May20171111341493827894.jpgCrown Equity Holdings Inc. (CRWE)

CRWE has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )

The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company’s services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.

CRWE's growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.

03May20171111341493827894.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. at www.crownequityholdings.com

**

Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer